Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live)
Action Represents Another Milestone for the Global Partnership Against Ebola
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ERVEBO® (Ebola Zaire Vaccine, Live) (pronounced er-VEE-boh) for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older. The duration of protection conferred by ERVEBO is unknown. ERVEBO does not protect against other species of Ebolavirus or Marburgvirus.
Media Contacts:
Pamela Eisele
267-305-3558
Skip Irvine
267-305-0338
Investor Contacts:
Peter Dannenbaum
908-740-1037
Michael DeCarbo
908-740-1807
Read Original Article: Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live) »
